Cancer News

Nexavar Improves Survival for Patients with Rare Sarcomas (03/28/2018)

Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug Nexavar (sorafenib tosylate) extended progression-free survival compared with a placebo. Progression-free survival is the length of time patients lived before their disease worsened. Based on these interim results, the data and safety monitoring board overseeing …

Continue reading "Nexavar Improves Survival for Patients with Rare Sarcomas"

Roadmap to Personalized Therapies for Sarcoma and other Aggressive Cancers (08/08/2017)

Sarcoma is a rare and deadly form of cancer occurring in the bones and connective tissue that affects individuals of all ages. Its aggressiveness, rarity and diversity continue to hinder efforts to identify effective therapies for people with this malignancy. Patient-derived orthotopic xenografts (PDOX) are unique models where a patient’s individual tumor is grown in …

Continue reading "Roadmap to Personalized Therapies for Sarcoma and other Aggressive Cancers"

Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation (03/16/2017)

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option.  However, a technique that limits the application of chemotherapy to the cancerous region can preserve limbs in a high percentage of these patients, researchers from five cancer centers in …

Continue reading "Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation"

Chemotherapy Before Surgery Improves Treatment of Sarcoma (11/07/2016)

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is called neoadjuvant therapy and has not previously been demonstrated to improve outcomes in soft tissue sarcoma (STS). Soft tissue … Continue reading "Chemotherapy Before Surgery Improves Treatment of Sarcoma"

Halaven Approved for Liposarcoma (02/04/2016)

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven is already approved for the treatment of advanced breast cancer. The approval indication for Halaven in the treatment of … Continue reading "Halaven Approved for Liposarcoma"